Chief Accounting Officer
Sarepta Therapeutics, Inc. (SRPT)Equibles does not estimate personal net worth.
Get an email with a short summary when Sarepta Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRPT alertsIan Estepan is recorded as COO at Sarepta Therapeutics, Inc. (SRPT) since July 16, 2025, Chief Accounting Officer at Sarepta Therapeutics, Inc. (SRPT) since December 14, 2020 and CFO at Sarepta Therapeutics, Inc. (SRPT). Sarepta Therapeutics, Inc. reported in an 8-K filed July 16, 2025 that Ian Estepan was appointed President and Chief Operating Officer, effective July 16, 2025. Ian Estepan has spoken on 18 earnings calls and 1 other investor event across 1 company, most recently for Sarepta Therapeutics, Inc. on March 3, 2026. Sarepta Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Sarepta Therapeutics, Inc. includes Douglas Ingram (CEO and Board Member), Michael Severino, M.D. (CEO and Board Member), M. Kathleen Behrens (Chairman) and 7 others.
“On July 14, 2025, the Board appointed Ian Estepan as the Company's President and Chief Operating Officer, Louise Rodino-Klapac, Ph.D. as the Company's President, Research and Development and Technical Operations, and Ryan Wong as the Company's Executive Vice President, Chief Financial Officer, each effective as of July 16, 2025.”
“And, of course, we'll be making a number of forward-looking statements. So before I get to your direct question, I think it's important to actually take a step back and think about the dynamics.”
“Building on Doug's message of decisive action, I want to reinforce Sarepta's commitment to remaining a vibrant enduring and patient-centric organization.”
“This afternoon's financial results press release provided details for the first quarter of 2025 on a GAAP basis as well as a non-GAAP basis. Please refer to our press release available on Sarepta's website for a full reconciliation of GAAP to non-GAAP financial results.”
“Before I review our financial results, I want to discuss quickly just three topics. First, I just want to add some color on our approach to revenue guidance.”
“This afternoon, financial results press release provided details for the first quarter of 2024 on a non-GAAP basis as well as the GAAP basis. Please refer to our press release available on Sarepta's website for a full reconciliation of GAAP to non-GAAP financial results.”
2025-07-16–present
2020-12-14–present
Biotechnology · Healthcare
CFO, COO, Chief Accounting Officer
2020-12-14–present
